Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;2(4):42-8.
doi: 10.1097/WOX.0b013e31819cdfdb.

Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years

Paolo Tassinari  1 , Nelson R Suárez, Jorge Centeno, Janina Vergara Velásquez, Héctor Aguirre-Mariscal, Sandra N Gonzálezdíaz, Alfredo Fernández de Córdova Jerves; LA Desloratadine Study Group
Affiliations

Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years

Paolo Tassinari et al. World Allergy Organ J. 2009 Apr.

Abstract

Objective: : To determine the effectiveness of desloratadine syrup in relieving symptoms of allergic rhinitis (AR) among children in Latin America.

Methods: : In an open-label trial conducted in 5 Latin American countries, 455 children aged 6 to 12 years with seasonal or perennial AR were treated with desloratadine syrup 2.5 mg/d for 6 weeks. Thirty percent of subjects were concomitantly taking corticosteroids, and 21.3% had a history of asthma. Efficacy was measured by improvement in the Total Symptom Severity 4 questionnaire and decrease in severity of individual nasal symptoms of congestion, rhinorrhea, pruritus, and sneezing. Physicians and subjects' caregivers rated symptom improvement in a separate assessment at final visit.

Results: : Treatment with desloratadine led to a significant decrease in mean Total Symptom Severity 4 score, from 7.54 at baseline to 1.96 at study end (P < 0.0001), and in individual symptom scores, including congestion (P < 0.0001 for all). Similar improvements were found in groups receiving desloratadine monotherapy and desloratadine plus corticosteroids. Allergic rhinitis symptoms were rated "better" or "much better" by 94% of caregivers. Incidence of adverse events was 6%.

Conclusions: : Desloratadine, with or without concomitant corticosteroids, was efficacious and safe in the treatment of AR in this group of Latin American children.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The Total Symptom Severity 4 questionnaire.
Figure 2
Figure 2
Percentage of children with moderate or severe symptoms of AR at baseline.
Figure 3
Figure 3
The TSS4 scores at baseline and after 6 weeks of desloratadine therapy in all subjects and according to the use of concomitant corticosteroid therapy.
Figure 4
Figure 4
Changes in individual symptom scores in all subjects and according to the use of concomitant corticosteroid therapy.
Figure 5
Figure 5
Caregivers' perceptions of improvement.
See this image and copyright information in PMC

References

    1. Richards W. Asthma, allergies, and school. Pediatr Ann. 1992;2:575–585. - PubMed
    1. Richards W. Preventing behavior problems in asthma and allergies. Clin Pediatr (Phila) 1994;2:617–624. doi: 10.1177/000992289403301008. - DOI - PubMed
    1. Blaiss MS. on behalf of The Allergic Rhinitis in Schoolchildren Consensus Group. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin. 2004;2:1937–1952. doi: 10.1185/030079904X13266. - DOI - PubMed
    1. Klein GL, Ziering RW, Girsh LS, Miller MF. The allergic irritability syndrome: four case reports and a position statement from the Neuroallergy Committee of the American College of Allergy. Ann Allergy. 1985;2:22–24. - PubMed
    1. Arrighi HM, Maier WC, Redding GJ, Morray BH, Llewellyn CE. The impact of allergic rhinitis in Seattle school children [Abstract 208] J Allergy Clin Immunol. 1995;2:192.